TriSalus (TLSI) Q4 2025 earnings review
Textbook Commercial Pivot Accelerates Revenue, But 2026 Guide Disappoints
TriSalus ended 2025 with an exceptional quarter, accelerating revenue growth to 60% YoY ($13.2M) and dramatically narrowing its Adjusted EBITDA loss to just $0.9M. The company's strategic pivot—halting internal R&D on its nelitolimod drug to focus entirely on its high-margin TriNav device business—is paying off. A new CMS reimbursement code and rapid product iteration (TriNav FLX, XP) drove deeper penetration in the core liver embolization market. Furthermore, a fresh $46M public offering effectively removes near-term funding overhangs. However, the 2026 revenue guidance of $60-62M implies a sharp deceleration to ~35% growth. Investors must weigh an excellent commercial execution story against a notably conservative forward outlook.
🐂 Bull Case
The Q4 Adjusted EBITDA loss shrank to just $0.9M (from $5.7M a year ago). With $46M in fresh capital and R&D costs continuing to fall, TriSalus is fully funded to reach free cash flow generation.
The CMS C8004 mapping code launched in April 2025 has been a massive success, effectively doubling reimbursable use for radioembolization and driving four consecutive quarters of accelerating top-line growth.
🐻 Bear Case
After exiting Q4 with 60% YoY growth, guiding for $60-$62M in FY26 implies a steep deceleration to ~35% growth, raising questions about whether the core liver market is nearing near-term saturation.
The strategy to eliminate drug R&D costs relies on finding a partner for nelitolimod. In a difficult biotech funding macro environment, failing to secure a partner could result in the asset being stranded without realizing its value.
⚖️ Verdict: 🟢
Bullish. While the 2026 guidance is uncharacteristically conservative given recent momentum, the fundamental operating leverage demonstrated in Q4 is stellar. TriSalus is transitioning from a cash-burning biotech into a high-margin, high-growth medtech commercial engine.
Key Themes
CMS Reimbursement Code C8004 Accelerating Adoption
The April 2025 introduction of CMS code C8004 for mapping procedures has been the primary catalyst for the year. By allowing physicians to receive reimbursement for using TriNav during the mapping phase of radioembolization, the code removed a major economic friction point, essentially doubling the device's billable usage per patient journey.
Rapid Product Expansion Driving Account Penetration
TriSalus is winning by providing a comprehensive toolkit. The recent launches of TriNav FLX (for tortuous anatomy) and the newly announced TriNav XP (engineered for larger embolic beads up to 700 μm) expand treatable patient populations. This dynamic is successfully shifting the commercial narrative from merely acquiring new hospital accounts to driving deeper utilization within existing ones.
Strategic Pivot: Abandoning Drug R&D for Device Growth
The most important financial theme of 2025 was the decision to halt internal development of the nelitolimod immunotherapeutic to focus purely on the PEDD device platform. This pivot triggered a deliberate reshuffling of operating expenses: substituting heavy clinical trial cash burn for scalable commercial sales and marketing investments.
Execution Risk in Expanding Beyond the Liver
To sustain long-term growth, management is aggressively targeting new indications like Uterine Fibroids (UAE), Thyroid Disease, and Genicular Artery Embolization (GAE) for knee pain. While the Total Addressable Market (TAM) for these is massive, commercializing into these new interventional radiology call points carries heavy execution risk and requires continued, elevated sales force investment.
Gross Margin Rebound Needs to Hold
Gross margins dipped to 84% in early-to-mid 2025 due to manufacturing inefficiencies related to scaling new products (like FLX and LD). While Q4 showed a Reversing trend back up to a healthy 86.7%, maintaining this efficiency while launching yet another new product (TriNav XP) will be a critical operational test in 2026.
Macro Environment Pressuring Biotech Partnerships
Management previously acknowledged that the broader biotech macro environment is 'not as robust'. This poses a direct risk to their stated strategy of finding an external partner to fund and advance nelitolimod. If a partnership fails to materialize, the asset may generate zero return on the heavy R&D investments made prior to 2025.
Guidance Contradicts Exiting Momentum
Q4 revenue grew 60% YoY, but the FY26 guidance implies a full-year growth rate of roughly 35%. This significant Deceleration contradicts management's highly bullish tone regarding commercial expansion, expanded sales headcount, and new TAM penetration. It suggests either extreme conservatism or an underlying expectation of headwinds in the core liver segment.
Other KPIs
Reversing. Margin improved from 85.3% in 24Q4 and up from the 84.0% seen in Q2 and Q3 of 2025. This indicates that the manufacturing inefficiencies tied to mid-year product launches are being resolved as production scales.
Cash ended Q4 at $20.4 million. Crucially, the company raised an additional $46 million in gross proceeds via a public offering subsequent to the quarter's end. With the Adjusted EBITDA loss shrinking to sub-$1M in Q4, the company is exceptionally well-capitalized to reach profitability without further dilution.
Accelerating. Up 14% YoY from $7.0M in 24Q4. This intentional ramp reflects performance-related compensation on record sales and the continued expansion of the commercial field team to cover new hospital accounts and indications.
Guidance
Decelerating. The midpoint of $61.0M represents an implied 35% YoY growth rate compared to FY25's $45.2M. While objectively strong for the medtech sector, it is a significant step down from the 53% growth achieved in FY25 and the 60% exit rate of Q4. This could be standard management sandbagging, or it may reflect the mathematical difficulty of sustaining >50% growth on a larger base without meaningful contributions from new, non-liver clinical applications.
Key Questions
Bridging the Guidance Gap
With Q4 revenue accelerating to 60% YoY, what specific headwinds or base effects are driving the conservative 35% implied growth at the midpoint of the 2026 guidance?
EBITDA Positivity Timing
Given that Q4 Adjusted EBITDA loss was narrowed to just $0.9 million, is the company now tracking ahead of its prior guidance to reach positive Adjusted EBITDA in the first half of 2026?
Nelitolimod Partnership Update
With the phase 1 clinical trials for nelitolimod wrapping up data completion, what is the realistic timeline for securing a partnership in the current biotech macro environment, and what structure is TriSalus seeking?
New Indication Revenue Contributions
How much of the $60-$62 million 2026 revenue guidance is expected to be driven by expansion into new non-liver applications such as Uterine Fibroids or Thyroid Disease, versus the core liver business?